160 related articles for article (PubMed ID: 36692657)
1. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer.
Zampella E; Piscopo L; Manganelli M; Volpe F; Nappi C; Gaudieri V; Pace L; Schlumberger M; Cuocolo A; Klain M
Endocrine; 2023 Jun; 80(3):612-618. PubMed ID: 36692657
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
3. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer.
Klain M; Zampella E; Piscopo L; Volpe F; Manganelli M; Masone S; Pace L; Salvatore D; Schlumberger M; Cuocolo A
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503148
[TBL] [Abstract][Full Text] [Related]
5. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
6. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.
Gao H; Huang J; Dai Q; Su J
Arch Endocrinol Metab; 2023 Mar; 67(2):197-205. PubMed ID: 36651706
[TBL] [Abstract][Full Text] [Related]
8. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
9. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
10. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
11. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
12. Retrospective case-control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer.
Watanabe K; Igarashi T; Uchiyama M; Ishigaki T; Ojiri H
Jpn J Radiol; 2024 Apr; 42(4):391-397. PubMed ID: 38212512
[TBL] [Abstract][Full Text] [Related]
13. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
Wang C; Zhao T; Li H; Gao W; Lin Y
Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
[TBL] [Abstract][Full Text] [Related]
14. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
[TBL] [Abstract][Full Text] [Related]
15. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
16. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
17. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
Wang Y; Wu J; Jiang L; Zhang X; Liu B
Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]